Literature DB >> 16051824

ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.

Neelam Sharma-Walia1, Harinivas H Krishnan, Pramod P Naranatt, Ling Zeng, Marilyn S Smith, Bala Chandran.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) in vitro target cell infection is characterized by the expression of the latency-associated genes ORF 73 (LANA-1), ORF 72, and K13 and by the transient expression of a very limited number of lytic genes such as lytic cycle switch gene ORF 50 (RTA) and the immediate early (IE) lytic K5, K8, and v-IRF2 genes. During the early stages of infection, several overlapping multistep complex events precede the initiation of viral gene expression. KSHV envelope glycoprotein gB induces the FAK-Src-PI3K-RhoGTPase (where FAK is focal adhesion kinase) signaling pathway. As early as 5 min postinfection (p.i.), KSHV induced the extracellular signal-regulated kinase 1 and 2 (ERK1/2) via the PI3K-PKCzeta-MEK pathway. In addition, KSHV modulated the transcription of several host genes of primary human dermal microvascular endothelial cells (HMVEC-d) and fibroblast (HFF) cells by 2 h and 4 h p.i. Neutralization of virus entry and infection by PI-3K and other cellular tyrosine kinase inhibitors suggested a critical role for signaling molecules in KSHV infection of target cells. Here we investigated the induction of ERK1/2 by KSHV and KSHV envelope glycoproteins gB and gpK8.1A and the role of induced ERK in viral and host gene expression. Early during infection, significant ERK1/2 induction was observed even with low multiplicity of infection of live and UV-inactivated KSHV in serum-starved cells as well as in the presence of serum. Entry of UV-inactivated virus and the absence of viral gene expression suggested that ERK1/2 induction is mediated by the initial signal cascade induced by KSHV binding and entry. Purified soluble gpK8.1A induced the MEK1/2 dependent ERK1/2 but not ERK5 and p38 mitogen-activated protein kinase (MAPK) in HMVEC-d and HFF. Moderate ERK induction with soluble gB was seen only in HMVEC-d. Preincubation of gpK8.1A with heparin or anti-gpK8.1A antibodies inhibited the ERK induction. U0126, a selective inhibitor for MEK/ERK blocked the gpK8.1A- and KSHV-induced ERK activation. ERK1/2 inhibition did not block viral DNA internalization and had no significant effect on nuclear delivery of KSHV DNA during de novo infection. Analyses of viral gene expression by quantitative real-time reverse transcriptase PCR revealed that pretreatment of cells with U0126 for 1 h and during the 2-h infection with KSHV significantly inhibited the expression of ORF 73, ORF 50 (RTA), and the IE-K8 and v-IRF2 genes. However, the expression of lytic IE-K5 gene was not affected significantly. Expression of ORF 73 in BCBL-1 cells was also significantly inhibited by preincubation with U0126. Inhibition of ERK1/2 also inhibited the transcription of some of the vital host genes such as DUSP5 (dual specificity phosphatase 5), ICAM-1 (intercellular adhesion molecule 1), heparin binding epidermal growth factor, and vascular endothelial growth factor that were up-regulated early during KSHV infection. Several MAPK-regulated host transcription factors such as c-Jun, STAT1alpha, MEF2, c-Myc, ATF-2 and c-Fos were induced early during infection, and ERK inhibition significantly blocked the c-Fos, c-Jun, c-Myc, and STAT1alpha activation in the infected cells. AP1 transcription factors binding to the RTA promoter in electrophoretic mobility shift assays were readily detected in the infected cell nuclear extracts which were significantly reduced by ERK inhibition. Together, these results suggest that very early during de novo infection, KSHV induces the ERK1/2 to modulate the initiation of viral gene expression and host cell genes, which further supports our hypothesis that beside the conduit for viral DNA delivery into the cytoplasm, KSHV interactions with host cell receptor(s) create an appropriate intracellular environment facilitating infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051824      PMCID: PMC1182676          DOI: 10.1128/JVI.79.16.10308-10329.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters.

Authors:  D M Lukac; L Garibyan; J R Kirshner; D Palmeri; D Ganem
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma.

Authors:  D Ganem
Journal:  Curr Clin Top Infect Dis       Date:  1998

3.  Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter.

Authors:  R Sarid; J S Wiezorek; P S Moore; Y Chang
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 4.  Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8).

Authors:  Thomas F Schulz; Julie Sheldon; Julie Greensill
Journal:  Virus Res       Date:  2002-01-30       Impact factor: 3.303

5.  Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1.

Authors:  A Birkmann; K Mahr; A Ensser; S Yağuboğlu; F Titgemeyer; B Fleckenstein; F Neipel
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate.

Authors:  F Z Wang; S M Akula; N P Pramod; L Zeng; B Chandran
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer.

Authors:  J M Le Doux; N Landazuri; M L Yarmush; J R Morgan
Journal:  Hum Gene Ther       Date:  2001-09-01       Impact factor: 5.695

8.  Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells.

Authors:  Shaw M Akula; Naranatt P Pramod; Fu Zhang Wang; Bala Chandran
Journal:  Cell       Date:  2002-02-08       Impact factor: 41.582

9.  Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor.

Authors:  Y Kato; R I Tapping; S Huang; M H Watson; R J Ulevitch; J D Lee
Journal:  Nature       Date:  1998-10-15       Impact factor: 49.962

10.  The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases.

Authors:  V Volmat; M Camps; S Arkinstall; J Pouysségur; P Lenormand
Journal:  J Cell Sci       Date:  2001-10       Impact factor: 5.285

View more
  109 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Regulation of Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhiqiang Qin; Lu Dai; Bryan Toole; Erle Robertson; Chris Parsons
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

Review 4.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

5.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes.

Authors:  Vivek Vikram Singh; Nagaraj Kerur; Virginie Bottero; Sujoy Dutta; Sayan Chakraborty; Mairaj Ahmed Ansari; Nitika Paudel; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.

Authors:  Zhiqiang Qin; Lu Dai; Michael Defee; Victoria J Findlay; Dennis K Watson; Bryan P Toole; Jennifer Cameron; Francesca Peruzzi; Keith Kirkwood; Chris Parsons
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Envelope glycoprotein gB of Kaposi's sarcoma-associated herpesvirus is essential for egress from infected cells.

Authors:  Harinivas H Krishnan; Neelam Sharma-Walia; Ling Zeng; Shou-Jiang Gao; Bala Chandran
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor.

Authors:  Young Bong Choi; John Nicholas
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin.

Authors:  Li-Wu Qian; Whitney Greene; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.